NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Century Therapeutics, Inc. (IPSC) Stock Analysis

Century Therapeutics, Inc. (IPSC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IPSC

$1.61

−$0.03 (−1.83%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IPSC with… →

IPSC Key Statistics

As of Oct 21, 2026
Trading
Open
$1.67
Previous Close
$1.64
Day's Range
1.53–1.67
52-Week Range
0.44–3.04
Volume
1.68M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.67
Valuation
Market Cap
$291.53M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.93
Financials (FY)
Revenue (FY)
$109.16M+1,556.76%
Net Income (FY)
−$9.58M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
181.08M
1-Year Return
+184.96%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
617.81K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IPSC closed at $1.61, +184.96% over 1 year.

Century Therapeutics, Inc. (IPSC) has a market capitalization of $291.53M.

In fiscal 2025, IPSC reported revenue of $109.16M.

IPSC Stock Return by Calendar Year

Century Therapeutics, Inc. (IPSC) return since Jun 2021: what $10,000 became

1 year
$10,000 $28,496
+184.96%
5 years
$10,000 $811
−91.89%
Since Jun 2021
$10,000 $705
−92.95%

If you had invested $10,000 in Century Therapeutics, Inc. (IPSC) at the close on June 18, 2021, the earliest close on record here, it would have been worth $705 at the close on October 21, 2026: −92.95% in total, −39.13% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+61.81%
2025−1.49%
2024−69.58%
2023−35.28%
2022−67.65%
2021 (partial year)−30.53%

As of October 21, 2026.

IPSC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$109.16M−$9.58M−8.8%
2024$6.59M−$126.57M−1,920.9%
2023$2.24M−$136.67M−6,115.1%
2022$5.20M−$130.93M−2,518.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$109.16M—−$10.51M−$9.58M−8.8%
2024$6.59M—−$133.81M−$126.57M−1,920.9%
2023$2.24M—−$125.18M−$136.67M−6,115.1%
2022$5.20M—−$123.83M−$130.93M−2,518.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Century Therapeutics, Inc. (IPSC) carries a market capitalisation of $291.53M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 78 employees.

Over the past 52 weeks the price has ranged from $0.44 to $3.04. The most recent close on file for IPSC is $1.61, dated October 21, 2026. That is −$0.03 (−1.83%) against the previous close. The latest close sits 270.11% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $109.16M. That is +1,556.76% against the prior fiscal year, when revenue was $6.59M. The same year closed with a net loss of $9.58M. Earnings per share on a trailing basis come to −0.93.

Across the 4 fiscal years on file, revenue moves from $5.20M in 2022 to $109.16M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is +184.96%. Across 5 years the annualized return works out at −39.50%. Beta against the wider market is reported at 1.67. Annualized volatility over the trailing 5 years is 82.83%.

Growth & Income

The record shows no dividend for IPSC.

Across the complete calendar years on file, 2025 returned −1.49% and 2024 returned −69.58%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the total return is +61.81% year to date.

Peer Comparison

Century Therapeutics, Inc. (IPSC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Century Therapeutics, Inc. IPSC $291.53M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Century Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Century Therapeutics, Inc.

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Visit website →